ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease

2021178 citationsJournal Articlehybrid Open Access

Authors

Madan Jagasia · Vanderbilt University

Aleksandr Lazaryan · Moffitt Cancer Center

Carlos Bachier · Centennial Medical Center

Amandeep Salhotra · City of Hope

Daniel J. Weisdorf · University of Minnesota

Behyar Zoghi · Methodist Hospital

James Essell ·

Abstract

Belumosudil treatment resulted in a high ORR and overall survival rate and demonstrated quality-of-life improvements, CS dose reductions, and limited toxicity. Data from the study indicated that belumosudil may prove to be an effective therapy for patients with treatment-refractory cGVHD.

Topics & Keywords

Hematopoietic Stem Cell Transplantation T-cell and B-cell Immunology Immune Cell Function and Interaction

Publication Details

Published in: Journal of Clinical Oncology

Volume 39, Issue 17, pp. 1888-1898

DOI: 10.1200/jco.20.02754

Field-Weighted Citation Impact: 17.38

Command Palette

ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease

Authors

Abstract

Topics & Keywords

Publication Details